Treatment of patients with high risk DLBCL

被引：0
|
作者：
Keller, U. [1 ]
机构：
[1] Tech Univ Munich, Innere Med 3, Munich, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V105
引用
收藏
页码：22 / 22
页数：1
相关论文
共 50 条
  • [1] Which treatment for high-risk patients with DLBCL?
    Coiffier, Bertrand
    LANCET ONCOLOGY, 2012, 13 (12): : 1180 - 1182
  • [2] Therapeutic strategies in high-risk DLBCL patients
    Viardot, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 42 - 42
  • [3] Timely Leukapheresis May Interfere with the "Fitness" of Lymphocytes Collected for CAR-T Treatment in High Risk DLBCL Patients
    Farina, Mirko
    Chiarini, Marco
    Almici, Camillo
    Buttini, Eugenia Accorsi
    Zuccala, Francesco
    Piva, Simone
    Volonghi, Irene
    Poli, Loris
    Bernardi, Simona
    Colnaghi, Federica
    Re, Federica
    Leoni, Alessandro
    Polverelli, Nicola
    Turra, Alessandro
    Morello, Enrico
    Galvagni, Anna
    Moratto, Daniele
    Brugnoni, Duilio
    Cattaneo, Chiara
    Ferrari, Emilio
    Bianchetti, Andrea
    Malagola, Michele
    Re, Alessandro
    Russo, Domenico
    CANCERS, 2022, 14 (21)
  • [4] Prognostic analysis of DLBCL patients and the role of upfront ASCT in high-intermediate and high-risk patients
    Zhao, Ying
    Wang, Hong
    Jin, Song
    Zheng, Jiajia
    Huang, Man
    Tang, Yaqiong
    Jin, Zhengming
    Qiu, Huiying
    Tang, Xiaowen
    Fu, Chengcheng
    Han, Yue
    Wu, De-Pei
    ONCOTARGET, 2017, 8 (42) : 73168 - 73176
  • [5] Cell of origin as a possible predictive marker for response to treatment with R-CHOEP in young high-risk patients with DLBCL
    Pedersen, Mette O.
    Gang, Anne O.
    Poulsen, Tim S.
    Knudsen, Helle
    Lauritzen, Anne F.
    Nielsen, Signe L.
    Klausen, Tobias W.
    Pedersen, Michael
    Brown, Peter
    Norgaard, Peter
    APMIS, 2014, 122 : 10 - 10
  • [6] CSF IGH REARRANGEMENT IN HIGH-RISK DLBCL PATIENTS TREATED WITH INTRATHECAL PROPHYLAXIS
    Tisi, M. C.
    D'Alo, F.
    Bellesi, S.
    Maiolo, E.
    Alma, E.
    Cuccaro, A.
    Chiusolo, P.
    Voso, M. T.
    Hohaus, S.
    HAEMATOLOGICA, 2016, 101 : 819 - 820
  • [7] DLBCL: treatment of elderly patients and relapsed disease
    不详
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2023, 16 : S119 - S120
  • [8] High-risk DLBCL: interim PET? Not yet
    Hertzberg, Mark
    BLOOD, 2017, 130 (11) : 1277 - 1278
  • [9] High Risk DLBCL in Younger Patients: Should ASCT be Declined in the Era Pos-Rituximab?
    Quintela, Miguel
    Vieira, Iolanda
    Moreira, Claudia
    Chacim, Sergio
    Domingues, Nelson
    Oliveira, Isabel
    Santo, Ana Espirito
    Moreira, Maria Ilidia
    Martins, Angelo
    Viterbo, Maria Luisa
    Pereira, Dulcineia
    Mariz, Jose Mario
    BLOOD, 2019, 134
  • [10] CNS relapse in young high-risk DLBCL patients - a joint analysis of LYSA and GLA
    Frontzek, F.
    Altmann, B.
    Ziepert, M.
    Casasnovas, O.
    Morschhauser, F.
    Oberic, L.
    Poeschel, V
    Fitoussi, O.
    Held, G.
    Glass, B.
    Ketterer, N.
    Renaud, L.
    Lenz, G.
    Mounier, N.
    Rosenwald, A.
    Ott, G.
    Molina, T.
    Parrens, M.
    Chartier, L.
    Tilly, H.
    Thieblemont, C.
    Schmitz, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 16 - 17
12345